Prescription Incentives: Unlocking Smoking Cessation Support or Creating Misalignment?
Prescriber incentives are a powerful tool to improve patient care, but can they inadvertently cause discrepancies in treatment? This question arises from a study presented at the 2025 ASHP Midyear Clinical Meeting & Exhibition, which revealed the impact of incentives on nicotine replacement therapy (NRT) prescribing at discharge.
Pharmacy Times delved into this topic with Taylor Fewox, PharmD, who shared intriguing insights. The study found that prescriber incentives significantly boosted NRT prescriptions upon discharge, but there's a twist. While more patients gained access to NRT, some prescriptions didn't align with the therapies received during their hospital stay. This raises an important question: Are incentives driving a shift in NRT use, or are they potentially leading to misaligned treatment plans?
Fewox explained that the initial motivation for the study was a report showing inadequate NRT prescribing in the psychiatry department. This prompted an evaluation of their own prescribing practices to ensure accuracy for patients. After implementing incentives, NRT prescriptions increased, with a notable rise in nicotine patches. However, this surge also led to some prescriptions that didn't match the inpatient therapies, indicating a potential gap in patient care.
The indigent fund played a crucial role in expanding access to NRT, ensuring more patients could receive smoking cessation support. Looking forward, Fewox and the team aim to refine the process through motivational interviewing and enhanced interdisciplinary collaboration. This approach aims to guide patients more effectively on their journey to quit smoking.
But here's where it gets controversial: Fewox suggests that while incentives have benefits, they may not always align with patient needs. Should incentives be tailored to individual patient requirements, or is a broader approach more effective?
The evaluation highlights the importance of interdisciplinary collaboration, involving pharmacists, psychiatrists, nurses, and tobacco cessation specialists. By working together, they can better understand each patient's journey and provide tailored tools for success. Fewox emphasizes the need to communicate patient progress and resource requirements to all team members, including attendings and psychiatrists.
And this is the part most people miss: The study underscores the complexity of balancing prescriber incentives with patient-centered care. While incentives can drive positive changes, they must be implemented thoughtfully to avoid unintended consequences.
As health systems and pharmacists strive to improve NRT prescribing and tobacco cessation outcomes, this study offers valuable lessons. By embracing interdisciplinary collaboration and patient-centric approaches, they can navigate the challenges of aligning incentives with personalized patient care.
What are your thoughts on the delicate balance between prescriber incentives and patient-specific treatment plans? Do you think incentives should be tailored to individual patient needs, or is a broader approach more practical? Share your opinions in the comments below, and let's spark a thoughtful discussion on this intriguing topic!
